Propanc Biopharma (PPCB) Accumulated Depreciation (2017 - 2025)

Propanc Biopharma (PPCB) posted quarterly Accumulated Depreciation of $25806.0 for Q4 2025, up 1.63% quarter-over-quarter from $25392.0 in Q3 2025.

Propanc Biopharma (PPCB) Accumulated Depreciation (2017 - 2025) Analysis & Trends

Propanc Biopharma (PPCB) has reported Accumulated Depreciation for 9 consecutive years, with $25806.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Accumulated Depreciation changed N/A year-over-year to $25806.0; the TTM figure through Dec 2025 stood at $25806.0 (changed N/A YoY), while the FY2025 annual figure was $25078.0, down 1.82% from the prior year.
Accumulated Depreciation improved to $25806.0 in Q4 2025 per PPCB's latest filing, from $25392.0 in the prior quarter.
Across five years, Accumulated Depreciation topped out at $27163.0 in Q3 2022 and bottomed at $23939.0 in Q3 2021.
Historically, Accumulated Depreciation has averaged $25222.1 across 5 years, with a median of $25078.0 in 2025.
Annual changes were most pronounced in 2021 — Accumulated Depreciation grew 18.57% — and 2023, when it declined 10.28%.
Propanc Biopharma's Accumulated Depreciation stood at $24631.0 in 2021, then rose by 1.04% to $24888.0 in 2022, then climbed by 4.27% to $25951.0 in 2023, then retreated by 1.57% to $25543.0 in 2024, then advanced by 1.03% to $25806.0 in 2025.
Business Quant data shows PPCB's Accumulated Depreciation at $25806.0 in Q4 2025, $25392.0 in Q3 2025, and $25078.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Propanc Biopharma	587,855.41	587,855.41	-

Download Data